Tofersen

(Qalsody®)

Qalsody®

Drug updated on 11/27/2023

Dosage FormInjection (intrathecal: 100 mg/15 mL (6.7 mg/mL) solution in a single-dose vial)
Drug ClassAntisense oligonucleotide
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene.

Product Monograph / Prescribing Information

Document TitleYearSource
Qalsody (tofersen) Prescribing Information. 2023Biogen MA Inc., Cambridge, MA

Randomized Controlled Trials

Document TitleSex DistributionYearSource
Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS.
108Subjects
F: 43%
M: 57%
2022New England Journal of Medicine
Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS.
50Subjects
F: 44%
M: 56%
2020New England Journal of Medicine

Sex Distribution:

F:43%
M:57%
108Subjects

Year:

2022

Source:New England Journal of Medicine


Sex Distribution:

F:44%
M:56%
50Subjects

Year:

2020

Source:New England Journal of Medicine